Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05558644 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Characterisation of the Immune Infiltrate and Molecular Features of Thymic Epithelial Tumors Tumors (TETs)

Study acronym: IMMUNO-TET
StatusRecruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion date: Oct 5, 2026 to Oct 2, 2028
    • Primary endpoints: 4 to 3
    • Study completion date: Oct 5, 2026 to Oct 2, 2029
    • Study title shortened, about 1 word
    v10
  2. Study title expanded, about 1 wordv9
  3. Re-verified, no change to tracked fieldsv8
  4. Site contacts updated at 1 of 3 sitesv7
  5. Primary endpoints revised (4)
    • Site contacts updated at 1 of 3 sites
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Study completion date: Oct 4, 2027 to Oct 5, 2026v5
  2. Primary completion date: Oct 5, 2027 to Oct 5, 2026v4 Show 4 more changesShow less
    • Study completion date: Oct 4, 2028 to Oct 4, 2027
    • Secondary endpoints: details revised at 5 of 5 entries
    • Study description expanded, about 231 words
    • Site details revised at 1 of 3 sites
  3. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Feb 15, 2026 to Oct 5, 2027
    • Start date changed from estimate of Apr 15, 2023 to Aug 3, 2023
    • Study sites: 0 to 3
    • Study completion date: Feb 15, 2027 to Oct 4, 2028
  4. Start date: Dec 15, 2022 to Apr 15, 2023
    • Eligibility criteria expanded, about 3 words
    • Study title shortened, about 1 word
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Institut Curie
43 trials monitored
See 1 trial at risk
The IMMUNO-TET trial aims to assess the feasibility of characterising the immune environment of TETs and the constitutional and somatic molecular profiles of patients with localised thymic epithelial tumour (TET).
Trial Details
NCT Number NCT05558644
Lead Sponsor Institut Curie
Conditions
(from sponsor)		 Cancer
Related terms Neoplasms
Enrollment 50 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov